

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Attorney's Docket: 0125-0016D3

Ţ	
54 <sub>P</sub>	
.i.6	
-გ	
1050 09/	` <b>\</b>
100	

:


Art Unit: 1631

Examiner: Y. Kim

SIR: This is a request for filing a


- [ ] Continuation [✓ ] Divisional Application under 37 C.F.R. § 1.53(b) of pending prior application Serial No. <u>09/390,326</u> filed <u>September 7, 1999</u> of <u>McTigue, et al.</u> for <u>Modifications of the VEGF Receptor-2 Protein and Methods of Use</u>
- [✓] Enclosed is a complete copy of the prior application including the oath or Declaration and drawings, if any, as originally filed. I hereby verify that the attached papers are a true copy of prior application Serial No. <u>09/390,326</u> as originally filed on <u>September 7, 1999</u>.
- 2. [✓] Cancel Claims 1-16.
- 3. [✓] A Preliminary Amendment is enclosed.
- 4. [✓] The filing fee is calculated on the basis of the claims existing in the prior application as amended at 2 and 3 above.

For	Number Filed	Nı	ımber Extra	Rate		Basic Fee \$710.00
Total						
Claims:	10	-20=	00	x\$ 18.0	0=	\$0
Independent						-
Claims:	1	<u>-</u> 3=	0	x\$ 80.0	0=	\$0
Multiple Depen (if applicable)	dent Claim(s)			+\$270.0	+\$270.00=	
,				Total	=	\$710.00
		Reduction by ½ for filing by small entity:				
	TOTAL FILING FEE			=:	\$710.00	



6. [✓] The Commissioner is hereby authorized to charge any fees which may be required including fees due under 37 C.F.R. § 1.16 and any other fees due under 37 C.F.R. § 1.17, or credit any overpayment during the pendency of this application to Deposit Account No. <u>50-0622</u>.

<ol><li>[✓] Amend the specification by inserting before the first line, the sentence:</li></ol>
This is a [ ] continuation [✓] division of application Serial No. 09/390,326, filed September 7, 1999 which is based upon application Serial No. 60/009,503, filed September 8, 1998
8. [ ] New formal drawings are enclosed.
9. [✓] The prior application is assigned of record to: Agouron Pharamceuticals, Inc.
10. [ ] Priority of application Serial No, filed on in (country) is claimed under 35 U.S.C. § 119. A certified copy
[ ] is enclosed or [ ] is on file in the prior application.
11. [ ] A verified statement claiming small entity status
[ ] is enclosed or [ ] is on file in the prior application.
12. [ ] The power of attorney in the prior application is to at least one of the following:
13. [✓] The power appears in the original declaration of the prior application.
14. [ ] Since the power does not appear in the original declaration, a copy of the power in the prior application is enclosed.
15. [✓] Please address all correspondence to SHANKS & HERBERT, TransPotomac Plaza, 1033 N. Fairfax St., Suite 306, Alexandria, VA 22314.
16. [✓] Recognize as associate attorney: Mark R. Shanks, Registration No. 33,781; Toni-Junell Herbert, Registration No. 34,348; Joseph Contrera, Registration No. 44,628; Christina Gadiano, Registration No. 37,628; Shelly Guest Cermak, Registration No. 39,571 of SHANKS & HERBERT; Linda Evans, Registration No. 33,873; Aubrey Haddach, Registration No. P-48,374; Ron Myers, Registration No. 43,825; Karl Neidert, Registration No. 39,313; Robert Prince, Registration No. 38,583; Joseph Reidy, Registration No. 39,390; Keith Hutchinson, Registration No. 43,687; and Jeffery Rennecker, Registration No. 40,784, of AGOURON PHARMACEUTICALS, INC.
[ ] Also enclosed is



Respectfully submitted,

**SHANKS & HERBERT** 

Shelly Guest Cermak

Reg. No.: 39,571

Date: <u>August 28, 2001</u>

TransPotomac Plaza 1033 N. Fairfax St., Suite 306 Alexandria, VA 22314 (703) 683-3600